Drug intelligence / Profile preview

Antispasmin

Development stage
Unknown
Lead developer
Stadmed
Modality
Small Molecules
Administration
Oral, Intramuscular
01

Overview

Antispasmin is a brand name for a line of antispasmodic medications developed and marketed by the Indian pharmaceutical company Stadmed. The most common formulation is a combination tablet containing **dicycloverine hydrochloride** (also known as dicyclomine) and **paracetamol** (acetaminophen). Dicycloverine is a tertiary amine that functions as a muscarinic receptor antagonist, providing relief from smooth muscle spasms in the gastrointestinal tract, biliary tract, and ureters. Paracetamol is included to provide analgesic effects for associated pain. Antispasmin is indicated for the treatment of functional bowel disorders, irritable bowel syndrome (IBS), and various forms of colic (biliary, renal, and intestinal). It is also available in other dosage forms, including injections and syrups, which typically contain dicycloverine as the sole active ingredient.

Brand names
Antispasmin
Other names
dicyclominedicycloverinedicyclomine + paracetamoldicycloverine + paracetamol
02

Targets

PDE4 (Phosphodiesterase 4A1)

Beyond the preview

Go deeper on Antispasmin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antispasmin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call